FDA Staff Questions Efficacy of Abbott's Xinlay, OSI's Tarceva Indication

Drug Industry Daily
KEYWORDS FDA / Rx
A A

FDA drug reviewers have raised doubts about the clinical benefits of two proposed cancer treatments — Abbott Laboratories’ experimental prostate cancer drug Xinlay and OSI Pharmaceutical’s proposed pancreatic cancer indication for Tarceva.

To View This Article:

Login

Subscribe To Drug Industry Daily